Rapid in vivo expansion of CAR T cells post infusion, often leading to cytokine release syndrome correlates with anti-tumor responses in hematological malignancies and has been frequently observed in clinical trials using CD19- and BCMA-redirected CARs (50, 51). The gene discussed is CD19; the disease is hematologic disorder.